References
  1. Nana A ,Gruessner A, Agopian VG, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg. 2015;150:252-259.
  2. Lamb KE, Lodhi S, Meier-Kriesche H-U. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant. 2011;11:450-462.
  3. Hart A, Smith JM, Skeans MA, Gustafson SK, et al. OPTN/SRTR 2017 Annual Data Report: Kidney. Am J Transplant. 2019;19 (Suppl 2):19-123.
  4. Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006;6:2006e12.
  5. Kuypers DR. Immunosuppressive drug therapy and subclinical acute renal allograft rejection: impact and effect. Transplantation. 2008;85 (Suppl 7):S25-30.
  6. Loupy A, Vernerey D, Tinel C, et al. Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts. Am J Soc Nephrol 2015;26:1721e31.
  7. Friedewald JJ, Kurian SM, Heilman RL, et al. Development and clinical validity of a novel blood‐based molecular biomarker for sub‐clinical acute rejection following kidney transplant. Am J Transplant 2019;19:98‐109.
  8. Hoffman W, Mehta R, Jorgensen DR, et al. The impact of early clinical and subclinical T cell-mediated rejection after kidney transplantation. Transplantation 2019; 103:1457-1467.
  9. Waldmann H. Drug minimization in transplantation. Curr Opin Organ Transplant 2014; 19:331-333.
  10. Metha R, Cherikh W, Sood P, Hariharan S. Kidney allograft surveillance biopsy practices across US transplant centers: A UNOS survey. Clin Transplant 2017; DOI: 10.1111/ctr.12945.
  11. Lee DM, Abecassis MM, Friedewald JJ, Rose S, First MR. Kidney Graft Surveillance Biopsy Utilization and Trends – Results from a Survey of High Volume Transplant Centers (Abstract, American Transplant Congress, Boston, MA, 2019.)
  12. Mengel M, Sis B, Halloran PF (2007) SWOT analysis of Banff: strengths, weaknesses, opportunities and threats of the international Banff consensus process and classification system for renal allograft pathology. Am J Transplant 7:2221-2226.
  13. Morgan TA, Chandran S, Burger IM, Zhang CA, Goldstein RB. Complications of ultrasound-guided renal transplant biopsies. Am J Transplant 2016;16:1298e305.
  14. Haas M, Loupy A, Lefaucheur C et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody- mediated rejection, and prospects for integrative endpoints for next- generation clinical trials. Am J Transplant 2017; DOI:10.1111/ajt.14625.
  15. Heilman R,Taber D, Guo K, et al.,Early subclinical rejection by biopsy or gene expression profile predicts long-term kidney function in patients in the CTOT 08 trial (Abstract, American Transplant Congress, Boston, MA, 2019.)
  16. Mehta R, Bhusal S, Randhawa P, et al. Short-term adverse effects of early subclinical allograft inflammation in kidney transplant recipients with a rapid steroid withdrawal protocol. Am J Transplant 2018;18:1710-1717.
  17. Nankivell BJ, Agrawal N, Sharma A, et al. The clinical and pathological significance of borderline T cell mediated rejection. Am J Transplant. 2018; DOI: 10.1111/ajt.15197.
  18. Seifert ME, Yanik MV, Feig DI, et al. Subclinical inflammation phenotypes and long-term outcomes after pediatric kidney transplantation. Am J Transplant. 2018;18: 2189-2199.
  19. Zhang W, Yi Z, Wei C, et al. Pretransplant transcriptomic signature in peripheral blood predicts early acute rejection. JCI Insight. 2019;4(11):e127543. https://doi.org/10.1172/jci.insight.127543.
  20. First MR, Pierry D, McNulty M, et al. Analytical and clinical validation of a molecular diagnostic signature in kidney transplant recipients. J Transplant Technol Res 7: 3. 2017; doi: 10.4172/2161-0991.1000176.
  21. First MR, Whisenant T, Friedewald JJ, et al. Clinical utility of peripheral blood gene expression profiling of kidney transplant recipients to assess the need for surveillance biopsies in subjects with stable renal function. J Transplant Technol Res 7: 3. 2017; doi: 10.4172/2161-0991.1000177.
  22. Marsh CL, Kurian SM, Rice JC, Whisenant TC, et al. Application of TruGraf v1: A novel molecular biomarker for managing kidney transplant recipients with stable renal function. Transplant Proc. 2019;51:722-728.
  23. First MR, Peddi VR, Mannon R, et al. Investigator assessment of the utility of the TruGraf molecular diagnostic test in clinical practice. Transplant Proc. 2019;51:729-733.
  24. Friedewald J, Abecassis M. Clinical implications for the use of a biomarker for subclinical rejection - Conflating arguments cause a disconnection between the premise and the conclusion. Am J Transplant. 2019;19(7): 2141-2142.